| Primary |
| Breast Cancer |
25.7% |
| Non-small Cell Lung Cancer |
17.5% |
| Ovarian Cancer |
9.8% |
| Breast Cancer Metastatic |
8.8% |
| Premedication |
6.5% |
| Product Used For Unknown Indication |
5.9% |
| Hypertension |
3.5% |
| Lung Neoplasm Malignant |
3.3% |
| Chemotherapy |
2.5% |
| Pain |
2.4% |
| Prophylaxis |
2.0% |
| Endometrial Cancer |
1.7% |
| Constipation |
1.6% |
| Gastric Cancer |
1.6% |
| Ovarian Epithelial Cancer |
1.6% |
| Nausea |
1.4% |
| Cervix Carcinoma |
1.2% |
| Diabetes Mellitus |
1.1% |
| Breast Cancer Stage Ii |
1.1% |
| Neoplasm Malignant |
1.0% |
|
| Vomiting |
12.8% |
| Dyspnoea |
6.9% |
| Tachycardia |
6.8% |
| Flushing |
6.3% |
| Infusion Related Reaction |
6.3% |
| Pyrexia |
5.8% |
| Hypersensitivity |
4.9% |
| Rash |
4.9% |
| Thrombocytopenia |
4.9% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
4.2% |
| Respiratory Failure |
4.2% |
| Loss Of Consciousness |
4.1% |
| Erythema |
3.7% |
| Pneumonia |
3.7% |
| Syncope |
3.7% |
| Sepsis |
3.6% |
| Cystoid Macular Oedema |
3.5% |
| Renal Failure Acute |
3.5% |
| Death |
3.2% |
| Scleroderma |
3.2% |
|
| Secondary |
| Breast Cancer |
31.1% |
| Non-small Cell Lung Cancer |
14.7% |
| Drug Use For Unknown Indication |
9.3% |
| Breast Cancer Metastatic |
7.1% |
| Product Used For Unknown Indication |
7.1% |
| Ovarian Cancer |
6.1% |
| Ovarian Epithelial Cancer |
3.4% |
| Prophylaxis |
2.8% |
| Premedication |
2.6% |
| Hypertension |
2.5% |
| Pain |
2.2% |
| Nausea |
2.1% |
| Lung Neoplasm Malignant |
1.7% |
| Chemotherapy |
1.3% |
| Constipation |
1.1% |
| Gastric Cancer |
1.1% |
| Metastatic Malignant Melanoma |
1.0% |
| Lung Adenocarcinoma |
0.9% |
| Fallopian Tube Cancer |
0.9% |
| Endometrial Cancer |
0.9% |
|
| Vomiting |
14.1% |
| Pyrexia |
10.1% |
| Neuropathy Peripheral |
7.9% |
| Neutropenia |
7.5% |
| Febrile Neutropenia |
5.8% |
| Thrombocytopenia |
5.8% |
| Pneumonia |
5.1% |
| White Blood Cell Count Decreased |
4.7% |
| Pulmonary Embolism |
4.4% |
| Dyspnoea |
4.1% |
| Sepsis |
4.1% |
| General Physical Health Deterioration |
3.4% |
| Death |
3.3% |
| Dehydration |
3.1% |
| Rash |
3.1% |
| Interstitial Lung Disease |
3.0% |
| Nausea |
2.7% |
| Syncope |
2.7% |
| Diarrhoea |
2.6% |
| Renal Failure |
2.5% |
|
| Concomitant |
| Breast Cancer |
22.5% |
| Drug Use For Unknown Indication |
13.7% |
| Breast Cancer Metastatic |
10.5% |
| Non-small Cell Lung Cancer |
6.9% |
| Metastases To Bone |
5.3% |
| Ovarian Cancer |
5.0% |
| Product Used For Unknown Indication |
4.9% |
| Premedication |
4.0% |
| Chemotherapy |
4.0% |
| Lung Adenocarcinoma |
3.4% |
| Malignant Peritoneal Neoplasm |
2.7% |
| Ovarian Cancer Recurrent |
2.7% |
| Lung Neoplasm Malignant |
2.5% |
| Lung Adenocarcinoma Metastatic |
2.4% |
| Prophylaxis |
2.2% |
| Pain |
1.9% |
| Cancer Pain |
1.7% |
| Hypertension |
1.4% |
| Oesophageal Carcinoma |
1.2% |
| Prophylaxis Of Nausea And Vomiting |
1.2% |
|
| Vomiting |
11.1% |
| Disease Progression |
8.4% |
| Death |
7.3% |
| White Blood Cell Count Decreased |
6.1% |
| Osteonecrosis Of Jaw |
5.7% |
| Pyrexia |
5.5% |
| Thrombocytopenia |
5.2% |
| Osteonecrosis |
4.9% |
| Sepsis |
4.6% |
| Febrile Neutropenia |
4.5% |
| Renal Failure Chronic |
4.5% |
| Weight Decreased |
4.5% |
| Interstitial Lung Disease |
4.2% |
| Pneumonia |
4.0% |
| Tooth Extraction |
4.0% |
| Ejection Fraction Decreased |
3.1% |
| Pain |
3.1% |
| Pneumothorax |
3.1% |
| Dyspnoea |
3.0% |
| Pulmonary Embolism |
3.0% |
|
| Interacting |
| Product Used For Unknown Indication |
25.9% |
| Breast Cancer |
20.4% |
| Lung Neoplasm Malignant |
11.1% |
| Drug Use For Unknown Indication |
9.3% |
| Nausea |
7.4% |
| Pain |
7.4% |
| Atrial Fibrillation |
3.7% |
| Breast Cancer Metastatic |
3.7% |
| Depression |
1.9% |
| Hiv Infection |
1.9% |
| Mucosal Inflammation |
1.9% |
| Ovarian Cancer |
1.9% |
| Ovarian Epithelial Cancer |
1.9% |
| Polycythaemia Vera |
1.9% |
|
| Drug Interaction |
14.3% |
| International Normalised Ratio Increased |
14.3% |
| Rash |
14.3% |
| Swelling |
14.3% |
| Fatigue |
7.1% |
| Pyrexia |
7.1% |
| Respiratory Failure |
7.1% |
| Thrombocytopenia |
7.1% |
| Toxic Skin Eruption |
7.1% |
| Uterine Disorder |
7.1% |
|
